Corey J. Langer, MD, discusses the need for reflex testing in patients with non–small cell lung cancer.
Advances in Risk-Stratification and Therapeutic Options for Early-Stage Non–Small Cell Lung Cancer
John F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.
Rodolfo Bordoni, MD, discusses the utility of adjuvant osimertinib in lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5